Press releases
- All
2024
November 29, 2024 IRLAB to present at ABGSC Investor Days on December 4, 2024
November 27, 2024 IRLAB to present at Redeye Technology & Life Science Day on December 3, 2024
November 21, 2024 / REGULATORY Nomination committee appointed for IRLAB’s annual general meeting 2025
November 13, 2024 IRLAB to Present at BioStock Life Science Summit 2024
October 30, 2024 / REGULATORY IRLAB publishes interim report for the period January – September 2024
October 29, 2024 IRLAB reports continued progress ahead of the mesdopetam Phase III program
October 28, 2024 IRLAB: Invitation to the interim report for Q3 2024 presentation and webcast
October 18, 2024 IRLAB presents at Redeye Neurology Theme Event
October 8, 2024 / REGULATORY IRLAB receives milestone payment of USD 2.5 million in conjunction with first dosing in a Phase I study with IRL757 in healthy older adults
October 3, 2024 Positive data from the first part of IRLAB’s Phase I study with the drug candidate IRL757
September 30, 2024 IRLAB has enrolled the last patient in the Phase IIb study of pirepemat
September 25, 2024 IRLAB presents at the International Congress of Parkinson’s Disease and Movement Disorders®(MDS) 2024
September 18, 2024 IRLAB granted additional patent for its drug candidate pirepemat expanding the patent protection in the US
September 13, 2024 IRLAB participates in Pareto Securities’ 15th Annual Healthcare Conference
September 6, 2024 IRLAB participates in the event Investing in life science: From seed to success
September 4, 2024 IRLAB is granted additional patent for drug candidate mesdopetam that expands its patent protection
July 10, 2024 / REGULATORY IRLAB publishes interim report for the period January-June 2024
July 8, 2024 IRLAB: Invitation to the interim report for Q2 2024 presentation and webcast
July 2, 2024 IRLAB’s Phase IIb study of pirepemat can proceed as planned after positive opinion from external safety committee
June 11, 2024 IRLAB participates in Stora Aktiedagarna
May 28, 2024 IRLAB presents at Redeye Growth Day 30 May
May 27, 2024 / REGULATORY IRLAB appoints Kristina Torfgård as new CEO
May 23, 2024 IRLAB strengthens its liquidity by drawing SEK 25 million on a previously secured loan facility
May 22, 2024 / REGULATORY Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB
May 22, 2024 IRLAB has administered the first dose in a Phase I clinical trial with the drug candidate IRL757
May 22, 2024 IRLAB broadcasts the annual general meeting live
May 21, 2024 IRLAB presents at ABGSC Investor Days
May 8, 2024 / REGULATORY IRLAB publishes interim report for the period January-March 2024
May 7, 2024 / REGULATORY IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
May 6, 2024 IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast
April 29, 2024 / REGULATORY IRLAB publishes Annual Report for 2023
April 16, 2024 IRLAB to present at Redeye Investor Forum
March 22, 2024 IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam
March 19, 2024 IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis
February 29, 2024 IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG
February 28, 2024 IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7
February 27, 2024 IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases
February 22, 2024 / REGULATORY IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam
February 7, 2024 / REGULATORY IRLAB publishes year-end report for the period January-December 2023
January 31, 2024 IRLAB: Invitation to the Year-end Report 2023 presentation and webcast
January 3, 2024 IRLAB is granted an end-of-Phase 2 meeting with the FDA for the Phase III-ready mesdopetam program
2023
December 27, 2023 / REGULATORY IRLAB extends CEO appointment
December 22, 2023 / REGULATORY IRLAB increases its liquidity with a loan facility of up to SEK 55 million that extends financial runway and increases business opportunities
December 21, 2023 / REGULATORY IRLAB receives grant from The Michael J. Fox Foundation to support development of IRL757 for the treatment of apathy
December 21, 2023 IRLAB’s drug candidate IRL757 is Phase I ready
December 18, 2023 IRLAB submits request for an end-of-Phase 2 meeting with the FDA for the Phase III-ready mesdopetam program
December 12, 2023 IRLAB is granted additional patent for drug candidate pirepemat that expands its patent protection
November 21, 2023 IRLAB to present at SEB Annual Healthcare Seminar on November 23, 2023
November 20, 2023 IRLAB to present at Redeye Life Science Day on November 23, 2023
November 20, 2023 IRLAB to present at ABGSC Investor Days on November 22, 2023
November 7, 2023 / REGULATORY Nomination committee appointed for IRLAB’s annual general meeting 2024
October 25, 2023 / REGULATORY IRLAB publishes interim report for the period January-September 2023
October 24, 2023 IRLAB to present at BioStock Life Science Fall Summit on October 26, 2023
October 19, 2023 IRLAB: Invitation to the interim report for Q3 2023 presentation and webcast
October 11, 2023 IRLAB shares invitation to Capital Markets Day on October 17, 2023
October 10, 2023 IRLAB to present at Redeye Neurology Theme Event on October 11, 2023
October 10, 2023 IRLAB signs Phase III regulatory US consultants to support preparation for mesdopetam’s end-of-Phase 2 meeting with the US FDA
September 13, 2023 IRLAB to present at Pareto Securities’ Healthcare Conference in Stockholm on September 14, 2023
September 11, 2023 Save the date: IRLAB holds Capital Markets Day on October 17, 2023
August 30, 2023 / REGULATORY IRLAB publishes interim report for the period January-June 2023
August 23, 2023 IRLAB: Invitation to the interim report for Q2 2023 presentation and webcast
August 21, 2023 IRLAB provides update on mesdopetam’s Phase IIb study data and the plans toward Phase III
August 21, 2023 / REGULATORY IRLAB secures full ownership of the mesdopetam project and continues product development
June 20, 2023 / REGULATORY Report from the Annual General meeting of IRLAB Therapeutics AB
June 20, 2023 IRLAB to present data from the Phase IIb study of mesdopetam in PD-LIDs at the MDS Congress 2023
June 13, 2023 IRLAB to present at the scientific conference XIV Triennial Meeting of the International Basal Ganglia Society (IBAGS)
June 1, 2023 IRLAB to present at Redeye Growth Day 2023 in Stockholm on June 1, 2023
May 30, 2023 IRLAB to present at ABGSC’s Life Science Summit in Stockholm on May 31, 2023
May 16, 2023 / REGULATORY IRLAB Therapeutics and the McQuade Center for Strategic Research and Development Enter into Agreement to Evaluate IRLAB’s Neuropsychiatric Programs IRL757 and IRL942
May 10, 2023 / REGULATORY IRLAB publishes interim report for the period January-March 2023
May 3, 2023 / REGULATORY IRLAB comments on statements in Ipsen’s 2022 Universal Registration Document and the further development of mesdopetam
May 3, 2023 IRLAB: Invitation to the interim report for Q1 2023 presentation and webcast
April 28, 2023 / REGULATORY IRLAB publishes the Annual Report for 2022
April 20, 2023 / REGULATORY IRLAB announces new date for publication of the annual report
March 22, 2023 IRLAB: Invitation to symposium on Parkinson’s disease and its management dilemma at the AD/PD™ 2023 on March 31, 2023
March 17, 2023 IRLAB to hold four presentations at scientific congress AD/PD™ 2023
March 6, 2023 IRLAB to present at ABGSC Investor Day in Stockholm on March 8, 2023
February 23, 2023 / REGULATORY IRLAB publishes Year-end report for the period January-December 2022
February 21, 2023 / REGULATORY IRLAB reports that board member leaves the company’s Board
February 20, 2023 / REGULATORY IRLAB changes CEO and appoints new Chairman
February 16, 2023 IRLAB: Invitation to the year-end report 2022 presentation and webcast
February 13, 2023 IRLAB updates on portfolio development milestones
January 17, 2023 / REGULATORY IRLAB announces top-line results from Phase IIb trial of mesdopetam (IRL790) in Parkinson’s disease
January 12, 2023 IRLAB nominates IRL1117 as drug candidate from the P003 project to develop a novel treatment for Parkinson’s disease
January 6, 2023 IRLAB to present at the 6th Neuroscience Innovation Forum in San Francisco on January 8, 2023
2022
December 21, 2022 IRLAB has been informed that the Swedish ECA investigation is closed
December 15, 2022 IRLAB to present at DNB Nordic Healthcare Conference in Oslo
December 14, 2022 IRLAB reports Last Patient Last Visit (“LPLV”) achieved in Phase IIb clinical study of mesdopetam in PD-LIDs with top-line results anticipated mid-January 2023
November 24, 2022 IRLAB to present at Redeye Life Science Day 2022
November 23, 2022 IRLAB to participate in the SEB Annual Healthcare Summit on November 23, 2022
November 15, 2022 IRLAB highlights new preclinical data indicating Phase IIb drug candidate mesdopetam’s powerful efficacy in Parkinson’s psychosis and PD-LIDs
November 15, 2022 / REGULATORY Nomination committee in IRLAB appointed ahead of annual general meeting 2023
November 14, 2022 IRLAB to participate at LSX Inv€$tival Showcase in London, UK
November 9, 2022 / REGULATORY IRLAB publishes interim report for the period January–September 2022
November 2, 2022 IRLAB: Invitation to the third quarter results presentation and webcast
October 11, 2022 IRLAB to present the company at Redeye Neurology Seminar on October 12, 2022
September 28, 2022 IRLAB to present the company at ProHearings on September 29, 2022
September 13, 2022 IRLAB to present at ABGSC Investor Day on September 13, 2022
September 12, 2022 IRLAB completes recruitment in Phase IIb study of mesdopetam (IRL790) in patients with Parkinson’s levodopa-induced dyskinesias
September 7, 2022 IRLAB to present at Pareto Securities’ 13th Annual Healthcare Conference
September 6, 2022 IRLAB’s partner Ipsen initiates clinical studies in line with mesdopetam’s development plan
August 31, 2022 IRLAB assists Swedish Economic Crime Authority
August 24, 2022 / REGULATORY IRLAB publishes interim report for the period January–June 2022
August 15, 2022 IRLAB: Invitation to the second quarter and half-year 2022 results presentation and webcast
August 1, 2022 / REGULATORY Changed number of shares and votes in IRLAB Therapeutics AB
July 11, 2022 / REGULATORY IRLAB expands Phase IIb/III PD-LIDs study with mesdopetam to support Phase III program and expects completion of enrollment during the summer
June 9, 2022 / REGULATORY IRLAB strengthens its management team by appointing Richard Godfrey as new CEO and Nicholas Waters as Executive Vice President and Head of R&D
May 11, 2022 / REGULATORY Report from the Annual General Meeting of IRLAB Therapeutics AB
May 11, 2022 / REGULATORY IRLAB interim report January – March, 2022
May 4, 2022 IRLAB announces invitation to presentation of the interim report for Q1 2022
April 22, 2022 / REGULATORY IRLAB acquires know-how connected to the P003 project aimed at an innovative treatment for Parkinson’s disease
April 11, 2022 / REGULATORY NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF 2022
April 8, 2022 / REGULATORY IRLAB publishes the Annual Report for 2021
March 21, 2022 IRLAB nominates new candidate drug, IRL757, to treat apathy in neurological disorders
March 18, 2022 Welcome to IRLAB’s Capital Markets Day 2022
February 23, 2022 Invitation to IRLAB’s Capital Markets Day 2022– Insights into our growth strategy
February 23, 2022 / REGULATORY IRLAB’s year-end report January 1 – December 31, 2021
February 16, 2022 Invitation to the presentation of IRLAB´s year-end report January – December 2021
2021
December 31, 2021 / REGULATORY Board member leaves IRLAB for another assignment
December 21, 2021 / REGULATORY IRLAB obtains regulatory approval to conduct Phase IIb study with pirepemat – one step closer to improving balance and reducing fall injuries for people living with Parkinson’s disease
November 10, 2021 / REGULATORY IRLAB publishes interim report for July 1 – September 30, 2021
November 5, 2021 / REGULATORY Nomination committee in IRLAB appointed ahead of annual general meeting 2022
November 5, 2021 Invitation to the presentation of IRLAB´s Interim report January – September 2021
September 2, 2021 IRLAB obtains strengthened patent protection for Phase II candidate pirepemat
August 25, 2021 / REGULATORY IRLAB publishes interim report for April 1 – June 30, 2021
July 16, 2021 IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam
July 15, 2021 / REGULATORY Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease
June 15, 2021 IRLAB’s drug candidate pirepemat’s Phase I data published in scientific journal CPDD
June 2, 2021 IRLAB announces that equity research company Edison initiates coverage of the company
May 25, 2021 IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P
May 6, 2021 / REGULATORY Report from the annual general meeting of IRLAB Therapeutics AB
May 6, 2021 / REGULATORY IRLAB interim report January – March 2021
May 5, 2021 IRLAB publishes recorded speech and company presentation prior to digital AGM
April 15, 2021 / REGULATORY IRLAB’s annual report for 2020 is now available on the company’s website
April 8, 2021 / REGULATORY IRLAB’s nomination committee proposes Martin Nicklasson as new board member and provides their proposal
March 25, 2021 IRLAB’s drug candidate mesdopetam’s mechanism of action receives confirmation by independent scientists
March 9, 2021 First European patients dosed in IRLAB’s Phase IIb/III mesdopetam study
February 24, 2021 / REGULATORY IRLAB’s Year-end report January 1 – December 31, 2020
January 29, 2021 / REGULATORY IRLAB announces change in share capital and number of shares following registered directed share issue
January 12, 2021 IRLAB presents application of deep learning on multidimensional CNS drug efficacy data
January 11, 2021 IRLAB presents new data indicating that mesdopetam could prevent dyskinesia in Parkinson’s Disease
2020
December 18, 2020 / REGULATORY IRLAB Therapeutics carries out a directed share issue in the amount of SEK 130,000,000
December 8, 2020 IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam
November 4, 2020 IRLAB starts Phase IIb/III study with mesdopetam in the US
October 30, 2020 / REGULATORY Nomination committee in IRLAB appointed ahead of annual general meeting 2021
October 1, 2020 / REGULATORY IRLAB’s mesdopetam IND accepted by the US FDA
September 30, 2020 / REGULATORY IRLAB’s shares are now traded on Nasdaq Stockholm Main Market
September 25, 2020 / REGULATORY IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market
September 23, 2020 / REGULATORY IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market
September 10, 2020 IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET
August 3, 2020 IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO
July 9, 2020 IRLAB’s clinical drug candidate IRL752 published in JPET
June 24, 2020 IRLAB’s mesdopetam featured on cover of top-tier publication JPET
June 4, 2020 IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON
May 7, 2020 / REGULATORY Report from the Annual General Meeting of IRLAB Therapeutics AB
May 6, 2020 IRLAB’s clinical drug candidate mesdopetam published in JPET
April 7, 2020 / REGULATORY IRLAB publishes the annual report for 2019
March 23, 2020 IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders
February 27, 2020 / REGULATORY IRLAB’s rights issue oversubscribed
February 7, 2020 / REGULATORY IRLAB publishes prospectus relating to the rights issue
February 6, 2020 / REGULATORY IRLAB launches new website
February 4, 2020 IRLAB’s IRL790 receives new name ‘mesdopetam’
2019
December 12, 2019 / REGULATORY IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million
December 12, 2019 / REGULATORY IRLAB intends to make a capital raise of approximately SEK 215 million
November 6, 2019 IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe
October 21, 2019 IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference
October 17, 2019 / REGULATORY Nomination committee in IRLAB appointed
September 26, 2019 / REGULATORY IRLAB’s IRL790 is proposed a unique INN by WHO
September 23, 2019 IRLAB presents at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
August 28, 2019 IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results
July 16, 2019 IRLAB reports top line results from Phase IIa study with IRL790
May 28, 2019 IRLAB and research consortium awarded MSEK 2.9 Vinnova grant
May 27, 2019 / REGULATORY Today, May 27, is the last day of trading in IRLAB’s share before share split
May 17, 2019 / REGULATORY IRLAB announces share split
April 25, 2019 / REGULATORY IRLAB – Resolutions at Annual General Meeting 2019
April 3, 2019 / REGULATORY IRLAB Therapeutics AB publishes annual report for 2018
March 14, 2019 IRLAB adds sites to Phase II study with IRL790 and passes DSMB’s second safety review
2018
December 18, 2018 IRLAB provides update on drug candidate IRL790’s clinical program
December 6, 2018 Nature’s npj Parkinson’s Disease publishes clinical study with IRLAB’s drug candidate IRL790
November 22, 2018 A new patent application for IRLAB’s drug candidate IRL752 has been published by World Intellectual Property Organization, WIPO
October 30, 2018 IRLAB provides in-depth information on results from successful Phase IIa study with IRL752 in Parkinson’s disease
September 26, 2018 IRLAB presents ISP at the CNS and Neurodegenerative Targets conference in Boston
September 20, 2018 Nomination committee appointed in IRLAB
September 19, 2018 IRLAB nominates two new candidate drugs and updates the pipeline
September 11, 2018 IRLAB Receives Notice of Allowance for U.S. Patent
August 30, 2018 IRLAB reports promising efficacy data from Phase IIa-study with IRL752
June 29, 2018 IRLAB reports top-line results from Phase IIa study with IRL752
May 23, 2018 / REGULATORY IRLAB Therapeutics has raised SEK 138.6 million in a directed share issue to top tier investors in the US and Sweden
May 17, 2018 / REGULATORY IRLAB prepares for listing on the Nasdaq Stockholm main market
May 16, 2018 / REGULATORY IRLAB – Resolutions at Annual General Meeting 2018
March 12, 2018 International attention on IRLAB’s discovery platform
January 31, 2018 IRLAB update on clinical Phase II pipeline – IRL752 and IRL790
2017
November 15, 2017 IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain
October 5, 2017 IRLAB receives approval from the Finnish MPA (Fimea)
October 4, 2017 IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia
September 20, 2017 / REGULATORY Nomination committee appointed in IRLAB
August 25, 2017 IRLAB receives approval to initiate Phase II trials with IRL752
August 17, 2017 IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790
August 17, 2017 IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790